Reproductive Partners Participates in New IVF Progesterone Delivery System Study
... in a national study to explore new IVF progesterone
delivery systems replacing intramuscular ... in a national, multi-center study exploring new progesterone
delivery systems to replace intramuscular ... in vitro fertilization (IVF) often describe the progesterone
injections as the most difficult and painful part ...
Nationwide Survey Shows Infertility Patients Prefer ENDOMETRIN(R) Compared With Other Progesterone Supplements
... and pain-free administration.
support is considered extremely important for a
successful pregnancy. Since natural progesterone
production may be
compromised by ART, progesterone
supplements are used extensively for
luteal phase ...
Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
... at risk for preterm delivery who can benefit
treatment, the March of Dimes Foundation said ... no prior history of preterm birth) who
suppository treatment between 24 and 34 ... those
women who are most likely to benefit from progesterone
treatment from those
who are not." Dr. Katz ...
Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
... New, Patient-Friendly progesterone
ATLANTA, Aug. 2 /PRNewswire/ -- ... (progesterone)
Vaginal Insert, 100 mg, a progesterone
supplement used in patients
undergoing assisted ... As the first new, patient-friendly
alternative to progesterone
supplementation in a decade, ENDOMETRIN was
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
... with metastatic TNBC, defined as tumors lacking
expression of estrogen and progesterone
receptors and without overexpression
of HER2, were randomly assigned to ... cancer, their tumors are
routinely tested for the presence of estrogen and progesterone
for the over-expression of HER2. Commonly used breast cancer ...
Methadone Frequently Causes Menopausal Symptoms in Young Women
... May 7 /PRNewswire/ -- Methadone medication frequently depresses estradiol, progesterone
and testosterone hormone levels to menopausal levels, even in women less ... 20 and 30 years old, who we detoxed from methadone arrived with estradiol, progesterone
or testosterone hormone levels, in the post menopausal range."
Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF
... 5 /PRNewswire/ -- Women undergoing in vitro
fertilization (IVF) require progesterone
medication to help support early
pregnancy, but the intramuscular ... forms of this medication
can be painful for patients. Formulations of progesterone
can be administered by subcutaneous injection or vaginal ...
Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
Reporting of Quantitative Estrogen Receptor and progesterone
Expression with Oncotype DX * A study presented by Kaiser Permanente ... other results, Genomic Health plans to provide individual estrogen and progesterone
receptor scores as an enhancement to Oncotype DX Recurrence Score ...
UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201
... III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), progesterone
Receptor (PR), and HER2-negative metastatic breast cancer.
Joyce O'Shaughnessy, M.D. , co-chair of the US Oncology Breast Cancer Research ...
Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
... work together to inhibit the growth of triple-negative breast cancer cells. "Triple-negative" refers to breast cancer cells that have no estrogen, progesterone
or HER2 receptors needed for currently-available, targeted anticancer therapies to work effectively.
AFP464 is now in Phase I clinical trials at ...
EntreMed Presents Initial Clinical Results for ENMD-2076
... human breast carcinoma model. Triple-negative breast cancer is a specific subtype of breast cancer that does not express estrogen receptor, progesterone
receptor, or Her2 genes. This subtype is more aggressive and less responsive to standard treatment and is also associated with poorer patient ...
Agendia Launches TargetPrint(R) for Breast Cancer Patients
... of TargetPrint(R), a new diagnostic test that
allows physicians to quantitatively determine the gene expression levels of
the estrogen receptor (ER), progesterone
receptor (PR) and Human Epidermal
growth factor Receptor 2 (HER2) in breast cancer tumor biopsies. The
accurate measurement of these receptors is of ...
Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies
... in intergroup trial E2197,"
(abstract 557) was led by the Eastern Cooperative Oncology Group (ECOG).
Researchers evaluated the predictive utility of progesterone
protein expression by IHC in a central lab and quantitative RNA expression
by RT-PCR for 371 genes, including the current Oncotype DX ...
Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy
... following St Gallen 1998
criteria: patient's age <35 years, tumor histological grade II/III, tumor
size >2 cm, or hormone-receptor (estrogen and/or progesterone
The 1059 women enrolled in this multicenter, phase III study were
randomized to receive either TAC (n=539) or FAC (n=520) ...
AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
... by measuring the functionality of
the estrogen signaling pathway inside the tumor cell itself. As such, H/I
goes beyond conventional estrogen and progesterone
testing. While patients who are ER/PR positive are assumed to benefit from
endocrine therapy, the therapy fails in approximately 25 ...
BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
... has initiated a Phase 2 study of its
lead PARP inhibitor, BSI-201, in patients with triple-negative breast
cancer that do not express the estrogen, progesterone
or HER2 receptors. The company designed the Phase 2 trial in this indication-which
represents a major unmet medical need-based on molecular ...
Ferring Reports on ENDOMETRIN Presentations at Pacific Coast
Reproductive Society Annual Meeting
Vaginal Supplement Studied in Largest-Ever IVF ... Ferring Pharmaceuticals' ENDOMETRIN(R), a
vaginal insert in development for luteal ... April 18
to 22, 2007.
ENDOMETRIN is micronized progesterone
in a tablet form that is
vaginally inserted with ...
Interim Analysis of Crinone Pregnancy Study to Be Published in
American Society for Reproductive Medicine Journal
... pregnancies in
400 women treated with CRINONE 8% progesterone
vaginal gel versus
intramuscular injections. The study is
being ... 8%.
"The fact that CRINONE 8% delivers the progesterone
achieve and maintain pregnancy has been ...
Columbia Laboratories Reports Preliminary Findings from the Ongoing
Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%
(progesterone gel) to Prevent Preterm Birth
... PROCHIEVE 8%, and suggest a correlation between the
cervical length data, progesterone
administration, and both a
reduction in the likelihood of preterm birth ... of Assisted Reproductive Technology
treatment for infertile women with progesterone
PROCHIEVE 4% (progesterone gel) for the treatment of ...
Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits
Potential for New Approach to the Treatment and Prevention of
... are induced via a known
carcinogenic compound. In the study, the hormone progesterone
shown to increase the number of growing tumors. Conversely, ... in 2005. Women whose primary lesions contain both estrogen
receptors are typically treated with
anti-estrogens or aromatase ...
Repros' Proellex Shows Statistically Significant Improvement in
Primary Endpoint in Phase 2 Trial in the Treatment of Uterine
... address conditions of the male and female reproductive
systems. Proellex(TM), the Company's lead compound, is a selective
blocker of the progesterone
receptor. Having successfully completed
the above Phase 2 trial the Company believes Proellex will enter
Phase 3 studies later this year for the ...
Newly Published Study Reveals Femara Improves Chances for Harder to
Treat Early Breast Cancer Relapse in Postmenopausal Women
... of early recurrence had tumours larger than five centimetres,
four or more positive nodes, positive oestrogen receptor status but
status, grade three tumours and invasive
disease. Notably, women with node positive disease, who are
considered to be at a higher risk of recurrence, ...
Columbia Laboratories Reports Positive Results from Multi-dose
Pharmacokinetic Study of Vaginally-administered Lidocaine
... drug delivery technology. Columbia markets CRINONE(R)
8% (progesterone gel) and PROCHIEVE(R) 8% (progesterone gel) in the
United States for progesterone
supplementation as part of an
Assisted Reproductive Technology treatment for infertile women with
progesterone deficiency and PROCHIEVE 4% ...